Strategic Funding Vivace recently closed a $35M Series D funding round led by RA Capital Management, boosting financial credibility and signaling readiness for commercialization efforts and potential partnerships or licensing discussions with larger biotech players.

Hippo-YAP Focus The company concentrates on first-in-class cancer therapies targeting the Hippo-YAP pathway with YAP-TEAD transcription activity inhibitors, presenting a clear niche for partnering on translational research, combination therapies, and companion diagnostic development.

Early Stage Scale With a lean team of 11-50 employees and a post-money valuation around $90M, Vivace represents an opportunity for early-stage collaboration in as-needed CRO support, preclinical-to-clinical a тас, and scalable R&D outsourcing relationships.

Genomics & Data Utilize their tech stack and data capabilities (MySQL, Google Analytics, Microsoft 365, HTTP/3) to propose integrated data management, bioinformatics, and cloud-based collaboration solutions that streamline research workflows and accelerate trial readiness.

Industry Positioning As a boutique oncology player with notable founders from UCSD and UCSF and a strategic Series D momentum, Vivace is a strong candidate for co-development, strategic alliances, or licensing discussions with larger biopharma aiming to diversify Hippo-YAP portfolios.